Qingrong Liu1,2, PhD; Ju Mei2,3, MD; Hongliang Zhang1, MD; Wenbing Zhou2, MBBS; Kejin Qiu4, MD; Qing Zhou2, MS; Yang Chen1, MD; Wei Duan2, MBBS; Changping Zhou2, MS; Min Tang3, MD; Jianbing Huang3, MD; Haixia Liu2, MBBS; Qingqing Liu2, MBBS; Rencao Chang4, MS; Guannan Niu1, MD; Yuxin Zhang4, MS; Tao Wu4, MS; Ting Zhang4, MS; Weiyi Fang2, MD; Yongjian Wu1,2, MD; Runlin Gao1, MD
1. Department of Cardiology, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China; 2. Department of Cardiology, Hefei High-Tech Cardiovascular Hospital, Anhui Province, China; 3. Department of Cardiothoracic Surgery, Xinhua Hospital, affiliated to Jiao Tong University School of Medicine, Shanghai, China; 4. Lepu Medical Technology (Beijing) Co., LTD, Beijing, China
Transcatheter aortic valve implantation (TAVI) has become a mainstay in treatment for severe symptomatic aortic stenosis (AS) patients1. Over the past decades, various transcatheter devices have been invented and tested for safety and efficacy2. This manuscript aims to report a novel device and initial experience with the SinoCrown system (Lepu Medical Technology [Beijing] Co., Ltd).
SinoCrown has numerous unique design features that distinguish it from other self-expanding valves. It is made up of a self-expanding nitinol stent and three valve leaflets which are made of bovine pericardial tissue (Figure 1). It was designed with a short stent that could ...
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
Read next article
Preclinical evaluation of the degradation kinetics of third-generation resorbable magnesium scaffolds